Herold Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.38M Sell
10,193
-251
-2% -$254K 2.06% 5
2025
Q4
$11.2M Sell
10,444
-97
-0.9% -$92.7K 2.51% 4
2025
Q3
$8.04M Buy
10,541
+823
+8% +$612K 1.86% 8
2025
Q2
$7.58M Sell
9,718
-818
-8% -$636K 1.59% 8
2025
Q1
$8.7M Sell
10,536
-984
-9% -$819K 1.91% 7
2024
Q4
$8.89M Buy
11,520
+158
+1% +$131K 1.94% 5
2024
Q3
$10.1M Sell
11,362
-294
-3% -$264K 2.19% 5
2024
Q2
$10.6M Buy
11,656
+213
+2% +$170K 2.44% 5
2024
Q1
$8.9M Buy
11,443
+559
+5% +$398K 2.15% 5
2023
Q4
$6.34M Sell
10,884
-215
-2% -$125K 1.76% 7
2023
Q3
$5.96M Buy
11,099
+2,031
+22% +$1.05M 1.81% 6
2023
Q2
$4.25M Sell
9,068
-83
-0.9% -$34.8K 1.3% 12
2023
Q1
$3.14M Sell
9,151
-1,358
-13% -$458K 1.09% 21
2022
Q4
$3.84M Buy
10,509
+1,500
+17% +$532K 1.63% 8
2022
Q3
$2.91M Sell
9,009
-560
-6% -$177K 1.4% 11
2022
Q2
$3.1M Sell
9,569
-145
-1% -$43.5K 1.38% 10
2022
Q1
$2.78M Buy
9,714
+100
+1% +$25.7K 0.99% 23
2021
Q4
$2.65M Hold
9,614
1.03% 21
2021
Q3
$2.22M Buy
+9,614
New +$2.37M 0.86% 24

Other funds holding LLY

Herold Advisors's LLY Position: Q1 2026 in Review

Herold Advisors reduced its Eli Lilly (LLY) stake by 2.4% in Q1 2026, selling an estimated $254K and leaving 10,193 shares worth $9.38M. The position accounts for 2.06% of the portfolio, ranked #5.

Herold Advisors first reported a position in LLY in Q3 2021 and has held it in 19 quarters since. The position peaked at $11.2M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Herold Advisors held 10,193 shares of Eli Lilly worth $9.38M as of Q1 2026.
  • Herold Advisors sold 251 Eli Lilly shares in Q1 2026, an estimated $254K.
  • Eli Lilly made up 2.06% of Herold Advisors's portfolio in Q1 2026, its #5 holding.
  • Herold Advisors first reported a position in Eli Lilly in Q3 2021 and has held it in 19 quarters since.
  • Herold Advisors's Eli Lilly position peaked at $11.2M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Herold Advisors's 13F filing for Q1 2026, filed 15 May 2026.